Genetically Guided Drug Development
Genetically Guided Drug Development
Research Topics uitklapper, klik om te openen
Our work focuses on providing early, in-human, evidence on the anticipated on-target effects of drug target perturbation against an array of clinically relevant traits. For this we have developed high throughput solution for drug target Mendelian randomization, loss-of-function analysis, and colocalization, alongside large sample size curated genomics databases. We aim to integrate of human genetics with (preclinical) drug development, to decrease cost and increase yield.
Key Publications uitklapper, klik om te openen
1. Schmidt AF et al. PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study, Lancet Diabetes & Endocrinoilogy 2017.
2. Schmidt AF et al. Genetic drug target validation using Mendelian randomization, Nature Communications 2020
3. Finan C et al. The druggable genome and support for target identification and validation in drug development, Science Translational Medicine 2017.
4. Schmidt AF et al. Cholesteryl Ester Transfer Protein (CETP) as a Drug Target for Cardiovascular Disease, Nature Communications 2021.
Facilities Involved uitklapper, klik om te openen
SMART
UCORBIO
People Involved uitklapper, klik om te openen
Contact uitklapper, klik om te openen
A Floriaan Schmidt
Folkert Asselbergs